Lanean...
Bortezomib in mantle cell lymphoma: comparative therapeutic outcomes
Mantle cell lymphoma (MCL) is an incurable, typically aggressive subtype of non-Hodgkin lymphoma, accounting for 4%–7% of newly diagnosed non-Hodgkin lymphoma cases. Chemoresistance commonly ensues in MCL, and patients with this heterogeneous disease invariably relapse, underscoring the unmet need f...
Gorde:
| Argitaratua izan da: | Ther Clin Risk Manag |
|---|---|
| Egile Nagusiak: | , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
Dove Medical Press
2015
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4644179/ https://ncbi.nlm.nih.gov/pubmed/26609233 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/TCRM.S72943 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|